持续释放的口服达尔法普利丁似乎对多发性硬化症患者的上肢功能没有影响:一项随机对照试验
Shay Menascu1, Lior Frid1, Alon Kalron2,3
1Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel.
Therapeutic advances in neurological disorders
|February 24, 2025
概括
在患有多发性硬化症 (pwMS) 的人群中,达尔法姆普里丁没有改善上肢功能. 这项研究表明药物治疗.
科学领域:
- 神经学 神经学
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 上肢功能障碍是多发性硬化症 (pwMS) 患者的常见和衰弱症状.
- 虽然已知dalfampridine可改善 pwMS 患者的步态,但其对上肢功能的影响尚不清楚.
研究的目的:
- 调查持续释放口服达尔法姆普里丁在增强 pwMS 上肢功能方面的疗效.
- 评估达尔法姆普里丁对上肢灵巧度,力量和感知到的功能能力的影响.
主要方法:
- 一个为期2周的随机,安慰剂对照试验,涉及30个pwMS接受达尔法姆普里丁 (每天两次10毫克) 或安慰剂.
- 用标准化临床测试 (例如,9-Hole Peg Test,握力) 和多个时间点的患者报告的结果措施来评估上肢功能.
主要成果:
- 在任何评估的上肢临床或自我报告的结果中,达尔法姆普里丁和安慰剂组之间没有发现统计学上显著的差异.
- 这两组在研究期间表现出相似的趋势,表明没有可测量的灵巧度,强度或功能改善,可归因于达尔法姆普里丁.
结论:
- 持续释放的dalfampridine似乎不会为患有多发性硬化症的人的上肢功能提供好处.
- 需要进一步的研究来确定有效的治疗上肢功能障碍在pwMS,超越步态改善.
关键词:
4 - 氨基胺-4-氨基胺-4-氨基胺-4-氨基胺范皮拉 (Fampyra) 是一个类型.达尔法姆普里丁 (dalfampridine) 是一种药物.手的手的手的手的手.多发性硬化症 多发性硬化症在上肢的上端.更多相关视频
07:35Author Spotlight: Rehabilitation of Stroke Patients With a Digital Occupational Training System
Published on: December 29, 2023
1.1K
05:28Author Spotlight: Enhancing Upper Limb Rehabilitation in Stroke Patients Through Advanced Robotic and Neuromodulation Technologies
Published on: October 11, 2024
463
相关概念视频
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:19Multiple Sclerosis l: Introduction
32
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
32